Intervacc announced that Jonas Sohlman would leave as CEO and Carl-Johan Dalsgaard was appointed CEO.
Intervacc develops novel veterinary vaccines based on recombinant proteins, aiming to improve animal health and welfare while reducing antibiotic use
Intervacc develops novel veterinary vaccines based on recombinant proteins, aiming to improve animal health and welfare while reducing antibiotic use. The company operates through its subsidiaries Nordvacc and Mybac-Vettech, focusing on vaccine marketing and diagnostics in the animal health sector.